je.st
news
Home
› MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
2015-05-07 18:57:31| Biotech - Topix.net
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that it has been notified by NINDS that the ongoing clinical trial of MN-166 in progressive multiple sclerosis is now fully enrolled. Enrollment activities at all 28 sites are now closed and no new patients will be accepted into the study.A Randomization is expected to be completed in approximately 4 - 6 weeks.
Tags: full
ms
trial
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||